• EL
  • EN

 

Log In

  • Forgot your password?
  • Forgot your username?
register

Newsletter

  • Home
  • Helios
    • About Us
    • The Board
    • Register
  • Epidemiology
  • Thanks
  • Useful tools
    • ProFaNE/FES-I
    • FRAX-WHO Fracture Risk Assessment Tool
    • GARVAN Fracture Risk Calculator
    • Cockcroft-Gault Calculator
    • BMD converter for DXA machines
  • Journal links
  • Contact Us
  • 000000
  • 00000000
  • 11-ISMNI_WEB BANNER
  • 41o
  • A1
  • ELIOS VOLOS 2023
  • JFSF-WebBnanner
  • Site_Banner_final_3
  • b_skeletal
  • books
  • image_slideshow_skeleton_2
  • slideshow_image_silhouette_2
  • WORLD OSTEOPOROSIS DAY

    Please click here to download the press release on World Osteoporosis Day

  • Εμβολιασμός κατά της νόσου COVID-19 & Θεραπεία της οστεοπόρωσης

  • Επικαιροποίηση των Κατευθυντήριων Οδηγιών του ΕΛΙΟΣ για την αναβολική θεραπεία

  • Ομιλίες από τη διαδικτυακή επιστημονική συνάντηση ΕΛΙΟΣ-ΕΕΜΜΟ "Φθινοπωρινές Ημέρες Οστεοπόρωσης"

    https://www.youtube.com/playlist?list=PLIyNelbH5Ev8zELelhxGgulrhs6gcl8fD

  • BMD After Transitioning From Denosumab to Alendronate

  • Approval of the marketing authorisation for Evenity (romosozumab)

    Approval of the marketing authorisation for Evenity (romosozumab)
    Re-examination leads to recommendation to approve


    After re-examining its initial opinion, the European Medicines Agency has recommended approving the marketing authorisation for the medicine Evenity for the treatment of severe osteoporosis.
    The Agency had initially refused the application on 27 June 2019 for Evenity to treat osteoporosis. After re-examination, on 17 October 2019 the Agency recommended that marketing authorisation could be granted but for a restricted indication in postmenopausal women with severe osteoporosis at high risk of fracture.
    The company that applied for authorisation was UCB Pharma S.A.

BMD After Transitioning From Denosumab to Alendronate

JMNI-SMNI

  • 21st Volume, 4th Issue, Octromber to December 2022

    Available only in Greek

Continue Reading

Monographs

  • Guidelines for the diagnosis and treatment of Osteoporosis in Greece 2017

    Guidelines for the diagnosis and treatment of Osteoporosis in Greece 2017

    Available only in Greek

  • Guidelines for the proper use of Calcium and Vitamin D supplements

    Guidelines for the proper use of Calcium and Vitamin D supplements

    Available only in Greek

Continue Reading
  • JMNI
  • Skeletal Health
  • HELIOS Monographs
  • CaseQuiz
  • Results of past polls
  • Past Scientific Meetings
  • Info for Patients
  • Events

Social Media

News on Metabolic Bone Diseases

  • 2019 ISCD Position Statement of ISCD

  • A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis

  • Diagnosis and Management of Paget’s Disease of Bone in Adults: A Clinical Guideline

Continue Reading

Poll

Woman aged 75 years with T-score at the femoral neck -1.8

I will estimate the 10-year probability of osteoporotic fracture with FRAX - 30%
I will perform an imaging assessment of spine - 6.7%
All the above - 63.3%

Total votes: 30
The voting for this poll has ended on: 29 May 2020 - 00:00

YouTube Channel

  • osteop World Osteoporosis Day

Site Map

  • Home
  • Helios
  • Epidemiology
  • Thanks
  • Useful tools
  • Journal links
  • Contact Us

Copyright © 2012-21 heliost.gr, All rights reserved./ terms of use / Contact